Cancers 2011, 3(3), 3687-3713; doi:10.3390/cancers3033687
Review

Emerging Cancer Vaccines: The Promise of Genetic Vectors

1 Takis, via di Castel Romano 100, 00128 Rome, Italy 2 BIOGEM scarl, via Camporeale, 83031 Ariano Irpino (AV), Italy 3 Dipartimento di Medicina Sperimentale e Clinica, Università degli studi di Catanzaro “Magna Graecia”, 88100 Catanzaro, Italy
* Author to whom correspondence should be addressed.
Received: 1 August 2011; in revised form: 9 September 2011 / Accepted: 14 September 2011 / Published: 22 September 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
PDF Full-text Download PDF Full-Text [333 KB, uploaded 22 September 2011 12:23 CEST]
Abstract: Therapeutic vaccination against cancer is an important approach which, when combined with other therapies, can improve long-term control of cancer. In fact, the induction of adaptive immune responses against Tumor Associated Antigens (TAAs) as well as innate immunity are important factors for tumor stabilization/eradication. A variety of immunization technologies have been explored in last decades and are currently under active evaluation, such as cell-based, protein, peptide and heat-shock protein-based cancer vaccines. Genetic vaccines are emerging as promising methodologies to elicit immune responses against a wide variety of antigens, including TAAs. Amongst these, Adenovirus (Ad)-based vectors show excellent immunogenicity profile and have achieved immunological proof of concept in humans. In vivo electroporation of plasmid DNA (DNA-EP) is also a desirable vaccine technology for cancer vaccines, as it is repeatable several times, a parameter required for the long-term maintenance of anti-tumor immunity. Recent findings show that combinations of different modalities of immunization (heterologous prime/boost) are able to induce superior immune reactions as compared to single-modality vaccines. In this review, we will discuss the challenges and requirements of emerging cancer vaccines, particularly focusing on the genetic cancer vaccines currently under active development and the promise shown by Ad and DNA-EP heterologous prime-boost.
Keywords: cancer vaccines; tumor associated antigens; adenoviral vectors; DNA electroporation

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Aurisicchio, L.; Ciliberto, G. Emerging Cancer Vaccines: The Promise of Genetic Vectors. Cancers 2011, 3, 3687-3713.

AMA Style

Aurisicchio L, Ciliberto G. Emerging Cancer Vaccines: The Promise of Genetic Vectors. Cancers. 2011; 3(3):3687-3713.

Chicago/Turabian Style

Aurisicchio, Luigi; Ciliberto, Gennaro. 2011. "Emerging Cancer Vaccines: The Promise of Genetic Vectors." Cancers 3, no. 3: 3687-3713.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert